Both in Biotechnology
Maze Therapeutics vs Recursion Pharmaceuticals
Over the past year MAZE returned −3.0% and RXRX returned −32.4%; their daily moves had a correlation of 0.21.
MAZE −3.0% RXRX −32.4%Growth of $1, one year, split-adjusted
| Metric | MAZE | RXRX |
|---|---|---|
| Price | $32.25 | $3.68 |
| Market cap | $1.79B | $2.20B |
| Today | +6.19% | −3.92% |
| 1 month | +22.0% | −23.0% |
| 6 months | +21.4% | +9.2% |
| Year to date | −22.2% | −10.0% |
| 1 year | −2.0% | −33.3% |
| Revenue growth (YoY) | — | +258.5% |
| Gross margin | — | 45.9% |
| Net margin | — | −641.6% |
| P/E (TTM) | — | — |
| Price / sales | 89.6× | 32.2× |
| Net cash | $372.1M | $538.0M |
| Dividend yield | — | — |
| Volatility (60d) | 67.4% | 95.4% |
| Short % of float | 18.8% | 37.5% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).